Literature DB >> 3903089

Association of penicillin tolerance with failure to eradicate group A streptococci from patients with pharyngitis.

K S Kim, E L Kaplan.   

Abstract

Despite uniform susceptibility of group A streptococci to penicillin, failure to eradicate group A streptococci is not uncommon in patients receiving penicillin for treatment of pharyngitis. We explored the possibility that penicillin tolerance could explain this phenomenon. We examined 48 group A streptococcal isolates from 48 patients successfully treated with penicillin (streptococci eradicated) and 92 isolates from 37 patients (one to four isolates per patient) who failed to respond to penicillin therapy (streptococci not eradicated). Penicillin tolerance was recognized by the gradient-replicate plate method and by time-kill experiments with penicillin concentrations of 16 times the minimal inhibiting concentrations. Tolerance was identified in 25% (23 of 92) of the isolates from the treatment failure group, in contrast to none of the strains from the treatment success group. Characterization of the strains by M and T typing revealed no predominant type(s) among the tolerant strains. These findings suggest that penicillin tolerance may be responsible for some instances of failure of penicillin to eradicate group A streptococci from the upper respiratory tract of individuals with streptococcal tonsillitis or pharyngitis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3903089     DOI: 10.1016/s0022-3476(85)80392-9

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  35 in total

1.  Prophylactic efficiency of 3-weekly benzathine penicillin G in rheumatic fever.

Authors:  B Oran; A Tastekin; S Karaaslan; L Bas; A Ayçiçek; A Ceri; A Sütçü; I Erkul
Journal:  Indian J Pediatr       Date:  2000-03       Impact factor: 1.967

2.  Streptococcal pharyngitis: is penicillin still the drug of choice?

Authors:  K R Rajesh; R C Gordon
Journal:  Indian J Pediatr       Date:  1996 Jul-Aug       Impact factor: 1.967

3.  Deregulation of the arginine deiminase (arc) operon in penicillin-tolerant mutants of Streptococcus gordonii.

Authors:  I Caldelari; B Loeliger; H Langen; M P Glauser; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

4.  Molecular DNA analysis for differentiation of persistence or relapse from recurrence in treatment failure of Streptococcus pyogenes pharyngitis.

Authors:  F Fitoussi; R Cohen; G Brami; C Doit; N Brahimi; F de la Rocque; E Bingen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-03       Impact factor: 3.267

Review 5.  Optimum treatment of streptococcal pharyngitis.

Authors:  F Scaglione; G Demartini; M M Arcidiacono; J P Pintucci
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

6.  Association of penicillin-tolerant streptococci with epidemics of streptococcal pharyngitis in closed communities.

Authors:  R Dagan; M Ferne
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-07       Impact factor: 3.267

7.  Penicillin tolerance of group A streptococci.

Authors:  C Betriu; E Campos; C Cabronero; A Fernandez; J J Picazo; A R Noriega
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-09       Impact factor: 3.267

8.  Comparative efficacy and safety of 3-day azithromycin and 10-day penicillin V treatment of group A beta-hemolytic streptococcal pharyngitis in children.

Authors:  L Pacifico; F Scopetti; A Ranucci; M Pataracchia; F Savignoni; C Chiesa
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

9.  Evaluation of potential factors contributing to microbiological treatment failure in Streptococcus pyogenes pharyngitis.

Authors:  S M Kuhn; J Preiksaitis; G J Tyrrel; T Jadavji; D Church; H D Davies
Journal:  Can J Infect Dis       Date:  2001-01

10.  Cefprozil versus penicillin V in treatment of streptococcal tonsillopharyngitis.

Authors:  D Milatovic; D Adam; H Hamilton; E Materman
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.